Your Partner in Translational Pharmaceutical Research

Pharmaceutical science is a key strategic research area within UniSA with an ERA ranking of 5 (outstanding performance well above world standard). The Pharmaceutical Innovation and Development Group (PIDG), led by Prof Sanjay Garg covers the full spectrum, from basic mechanistic studies to preclinical and clinical product development. Our interdisciplinary research is based on the principles of engagementinnovationtranslation and impact. With a patient and partnership-driven approach, PIDG is a one-stop destination for progressing molecules to medicines, ensuring significant savings of time and resources. The team excels in solving difficult product development challenges such as poor solubility, stability, and the need for local and systemic drug targeting. PIDG work closely with several companies developing human and veterinary pharmaceutical, biotechnological, complementary, nutrition and cosmetics products.

Our research

PIDG delivers customised R&D solutions to fulfil your product development requirements from preformulation, formulation, manufacturing (at pilot scale) to technology transfer, and developing alternate formulations for late lifecycle challenges. Our industry engagement is tailored to each collaborator/client with agreed intellectual property (IP) arrangement and can include "fee for service", collaboration, consulting or hybrid models. We specialise in partnerships for generating funding under the joint industry-academia programs such as ARC Linkage and CRC-P programs. 

The PIDG team excels in offering the following services to companies developing human and veterinary pharmaceutical, biotechnological, complementary, nutrition, aquaculture and cosmetics products.

  • analyse-data Analysis and Bioanalysis minus-thin plus-thin
    • Drug release and stability studies
    • Analytical method development, validation and optimisation of complex test procedures
    • Quantitation of test compounds in biological samples (plasma, blood, urine, tissues)
    • Raw material testing, product characterisation and stability assessment
    • Identification and evaluation of degradation products, metabolites; stress testing for stability indicating method
    • Compendial verification and qualification
    • Transfer of analytical procedures.
  • pills-medicine New Drug Development minus-thin plus-thin
    • Preformulation:
      • Solubility and stability assessment and improvement
      • Solid state characterization
      • Polymorphism etc.
    • Preclinical and clinical drug development
    • Formulations supplies for in-vitro, ex-vivo, and in-vivo safety and efficacy studies
    • Process optimisation and validation
    • Scale up and Technology transfer.
  • bottle-pills-medicine Dosage Form Design minus-thin plus-thin
    • Conventional dosage forms including solid (tablets, capsules, beads), semi-solid (gel, cream, ointment, paste, suppositories) and liquid (solution, suspension, emulsions)
    • Novel dosage forms:
          • Modified release: Fast acting, long acting, pulsed, sustained, delayed, and enteric
          • Improvement of physicochemical characteristics e.g. solubility, stability, metabolism, permeability, bioavailability and taste
          • Site specific delivery: localised or systemic
  • pills-tablet-medicine Advanced Delivery Systems minus-thin plus-thin
    • Nanotechnology: Mesoporous silica nanoparticles, liposomes, micelles, polymeric nanoparticles, lipid nanoparticles, nanoemulsion, nanocrystals, nanosuspension
    • Coating and Encapsulation:  conventional pan coating, Fluid bed coating, spray dryer, dip coating, extrusion/spheronisation
    • Novel drug delivery systems: Solid dispersion, films, implants, lipid suspension, microparticles, microcapsules, microspheres, pellets, in-situ gel, co-solvent, coated stents
    • Drug loaded medical devices: Hydrogel
    • 3D printing technology for precision therapy.
  • dog-pet-leash Veterinary Formulations minus-thin plus-thin
    • Formulations for dogs, cats, cows, horses, pigs, and fish
    • Dosage forms including: 
          • Intramammary delivery systems
          • Semi-solid topical formulations
          • Modified release pellets
          • Long acting injectables
          • Sustained release otic formulation
          • Suppositories
          • Single layer and bilayer tablets
          • Palatable oral formulations
          • Drug loaded feed and pour-on.
  • person-database-report Pharmacokinetics minus-thin plus-thin
    • PK Studies determine drug behaviour in the animal body and facilitate critical decision making on drug dosage and safety. PIDG provides the full range including protocol design, ethics submission, conduct study using mice or rat model and generate the PK sample analysis data using a fully validated bioanalytical assay to evaluate relevant PK parameters such as bioavailability, distribution, metabolism, and clearance.


Sanjay Garg
Professor of Pharmaceutical Science, UniSA Clinical & Health Sciences
HB6-11, City West Campus
May Song
Research Fellow, UniSA Clinical & Health Sciences
HB5-25, City West Campus
Franklin Afinjuomo
Research Assistant, UniSA Clinical & Health Sciences
HB5-25, City West Campus


Ankit Parikh
Adjunct Research Associate, UniSA Clinical & Health Sciences

HDR students

  • Pivian Sim
  • Isaac Deng
  • Sadikalmahdi Abdella
  • Souha Youssef


  • Fatima Abid
  • Sangseo Kim
  • Krishna Kathawala
  • Vivek Makwana